Metabolomics and lipidomics have emerged as tools in understanding the connections of metabolic syndrome (MetS) with cardiovascular diseases (CVD), type 1 and type 2 diabetes (T1D, T2D), and metabolic dysfunction-associated steatotic liver disease (MASLD). This review highlights the applications of these omics approaches in large-scale cohort studies, emphasizing their role in biomarker discovery and disease prediction. Integrating metabolomics and lipidomics has significantly advanced our understanding of MetS pathology by identifying unique metabolic signatures associated with disease progression. However, challenges such as standardizing analytical workflows, data interpretation, and biomarker validation remain critical for translating research findings into clinical practice. Future research should focus on optimizing these methodologies to enhance their clinical utility and address the global burden of MetS-related diseases.

• MeSH
• Biomarkers metabolism   MeSH
• Diabetes Mellitus, Type 1 metabolism   complications   MeSH
• Diabetes Mellitus, Type 2 * metabolism   MeSH
• Cardiovascular Diseases * metabolism   diagnosis   MeSH
• Humans MeSH
• Lipidomics * methods   MeSH
• Metabolic Syndrome * metabolism   MeSH
• Metabolomics * methods   MeSH
• Fatty Liver metabolism   MeSH
• Animals MeSH
• Check Tag
• Humans MeSH
• Animals MeSH
• Publication type
• Journal Article MeSH
• Review MeSH
• Names of Substances
• Biomarkers MeSH